Samyang Holdings Corporation

About Samyang Holdings Corporation

Samyang Holdings Corporation is specialized in commercialization of first generics and drug delivery system (DDS)-based modified drugs for cancer tratment and development of small-molecule drugs, new biologic drugs, and cancer virus vaccines. 

Samyang is exporting its oncology products to more than 25 countries, and its cytotoxic manufacturing facility is authorized by authorities from Korea, Europe, and Japan. To expand its Contract Development & Manufacturing, Samyang is constructing a new facility which is expected to achieve full cGMP operation, and the construction will be...

Certifications
  • KR
  • 2022
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Other
Pharmaceutical company
Primary activities
API Producer
Contract Manufacturer
Other
Pharmaceutical Company (generic finished products)
Contact info

Products from Samyang Holdings Corporation (3)

  • FPFs

    Product FPFs

    • Genexol®PM Inj.(Paclitaxel)   • Genexol® Inj.(Paclitaxel) • Nanoxel®M Inj.(Docetaxel) • Docetaxel Inj.(Docetaxel) • Nexatin® Inj.(Oxaliplatin) • Everose® Tab.(Everolimus) • Pemed®S Inj.(Pemetrexed) • Azalid® Inj.(Azacitidine) • Decilid® Inj.(Decitabine) • Lenalid® Inj.(Lenalid...
  • APIs

    Product APIs

    • Paclitaxel (Package : Up to 500g Per request) • Pemetrexed (Package : Up to 1kg Per request) • Bortezomib (Package : Up to 40g Per request)
  • CDMO

    Product CDMO

    • Cytotoxic Injection (Liquid , Lyophilized) • ONCOLOGY  • CYTOTOXIC API • EU GMP  • JGMP (Japan) • KGMP (Korea) • PIC/S

Samyang Holdings Corporation Resources (1)